M Sousa Bone Marrow Transplantation Ipo Lisboa

M sousa bone marrow transplantation ipo lisboa

1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al. Nat Cancer Inst; Bethesda, MD: 2017. SEER Cancer Statistics Review (CSR), 1975–2014. [Google Scholar]

2. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, et al.

Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood. 1999;94:2208–2216. [PubMed] [Google Scholar]

3.

Follow journal

Juric MK, Ghimire S, Ogonek J, Weissinger EM, Holler E, van Rood JJ, Oudshoorn M, Dickinson A, Greinix HT. Milestones of hematopoietic stem cell transplantation-from first human studies to current developments. Front Immunol. 2016;7:470. doi: 10.3389/fimmu.2016.00470.[PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q.

Associated Data

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012;5:46. doi: 10.1186/1756-8722-5-46.[PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Fan J, Jing M, Yang M, Xu L, Liang H, Huang Y, Yang R, Gui G, Wang H, Gong S, et al.

Journal list menu

Herpesvirus infections in hematopoietic stem cell transplant recipients seropositive for human cytomegalovirus before transplantation. Int J Infect Dis. 2016;46:89–93.

doi: 10.1016/j.ijid.2016.03.025. [PubMed] [CrossRef] [Google Scholar]

6. Funke VA, Moreira MC, Vigorito AC. Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation. Rev Assoc Med Bras (1992) 2016;62(Suppl 1):S44–S50. doi: 10.1590/1806-9282.62.suppl1.44.

Program – English

[PubMed] [CrossRef] [Google Scholar]

7. Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant.

2015;21:959–970. doi: 10.1016/j.bbmt.2014.11.676.

M sousa bone marrow transplantation ipo lisboa

[PubMed] [CrossRef] [Google Scholar]

8. Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G, et al.

M sousa bone marrow transplantation ipo lisboa

Impact of donor Epstein-Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: A study from the acute leukemia and infectious diseases working parties of the European society for blood and marrow transplantation.

J Clin Oncol. 2016;34:2212–2220. doi: 10.1200/JCO.2015.64.2405. [PubMed] [CrossRef] [Google Scholar]

9. Janani MK, Malathi J, Rela M, Farouk M, Padmapriya J, Madhavan HN.

M sousa bone marrow transplantation ipo lisboa

Genotypic detection of Epstein Barr virus in pediatric transplant recipients from India. Indian Pediatr. 2015;52:946–950. doi: 10.1007/s13312-015-0750-7. [PubMed] [CrossRef] [Google Scholar]

10. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases.

Link intime ipo allotment status galaxy

Transpl Infect Dis. 2009;11:383–392. doi: 10.1111/j.1399-3062.2009.00411.x. [PubMed] [CrossRef] [Google Scholar]

11. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P. Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN): Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Bone Marrow Transplant for Lymphoma

Haematologica. 2016;101:803–811. doi: 10.3324/haematol.2016.144428.[PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Solano C, Mateo EM, Pérez A, Talaya A, Terol MJ, Albert E, Giménez E, Vinuesa V, Piñana JL, Boluda JCH, Navarro D.

Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?

Instituto de Medicina Molecular (iMM) - Coordinating Institution

J Clin Virol. 2017;97:26–32. doi: 10.1016/j.jcv.2017.10.016. [PubMed] [CrossRef] [Google Scholar]

13. Marinho-Dias J, Lobo J, Henrique H, et al. Post-transplant lymphoproliferative disease in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012. Mol Med Rep (In press) 2018 doi: 10.3892/mmr.2018.9433. [PubMed] [CrossRef] [Google Scholar]

14.

Marinho-Dias J, Sousa H. Cytomegalovirus infection and cervical cancer: From past doubts to present questions. Acta Med Port. 2013;26:154–160.

M sousa bone marrow transplantation ipo lisboa

[PubMed] [Google Scholar]

15. Henig I, Zuckerman T.

M sousa bone marrow transplantation ipo lisboa

Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. Rambam Maimonides Med J. 2014;5:e0028. doi: 10.5041/RMMJ.10162.[PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies.

Curr Hematol Malig Rep. 2013;8:173–183. doi: 10.1007/s11899-013-0162-5.[PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Sousa H, Boutolleau D, Ribeiro J, Teixeira AL, Pinho Vaz C, Campilho F, Branca R, Campos A, Jr, Baldaque I, Medeiros R. Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: A five-year retrospective review.

Usa regulated forex account management company

Biol Blood Marrow Transplant. 2014;20:1958–1967. doi: 10.1016/j.bbmt.2014.08.010. [PubMed] [CrossRef] [Google Scholar]

18. Campos AB, Ribeiro J, Boutolleau D, Sousa H. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: Current state of the art. Rev Med Virol. 2016;26:161–182. doi: 10.1002/rmv.1873. [PubMed] [CrossRef] [Google Scholar]

19.

Prof. João Mascarenhas Forjaz Lacerda, MD PhD

Campos AB, Ribeiro J, Pinho Vaz C, Campilho F, Branca R, Campos A, Jr, Baldaque I, Medeiros R, Boutolleau D, Sousa H. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.

Antiviral Res. 2017;138:86–92. doi: 10.1016/j.antiviral.2016.10.016.

Ipo raising capital order

[PubMed] [CrossRef] [Google Scholar]

20. Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.

Clin Infect Dis. 2004;39:1016–1023. doi: 10.1086/424447. [PubMed] [CrossRef] [Google Scholar]

21. Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant.

2010;16:287–291. doi: 10.1016/j.bbmt.2009.10.008.[PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood.

12th Annual EBMT Patient, Family & Donor Day

2001;98:972–978. doi: 10.1182/blood.V98.4.972. [PubMed] [CrossRef] [Google Scholar]

23. Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, et al.

Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: A Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.

Bone Marrow Transplant. 2013;48:253–256. doi: 10.1038/bmt.2012.117. [PubMed] [CrossRef]